Last reviewed · How we verify
Denosumab Prefilled Syringe [Prolia]
Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents osteoclast formation and activation, thereby reducing bone resorption.
Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents osteoclast formation and activation, thereby reducing bone resorption. Used for Postmenopausal osteoporosis in women at high risk of fracture, Bone loss in patients with prostate cancer receiving androgen deprivation therapy, Bone loss in patients with breast cancer receiving aromatase inhibitors.
At a glance
| Generic name | Denosumab Prefilled Syringe [Prolia] |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | RANKL inhibitor (monoclonal antibody) |
| Target | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
By inhibiting RANKL signaling, denosumab suppresses osteoclast-mediated bone resorption without directly affecting bone formation. This leads to increased bone mineral density and reduced fracture risk in patients with osteoporosis or bone loss conditions. The drug is administered as a subcutaneous injection, typically every 6 months for osteoporosis treatment.
Approved indications
- Postmenopausal osteoporosis in women at high risk of fracture
- Bone loss in patients with prostate cancer receiving androgen deprivation therapy
- Bone loss in patients with breast cancer receiving aromatase inhibitors
- Giant cell tumor of bone
Common side effects
- Hypocalcemia
- Back pain
- Pain in extremity
- Musculoskeletal pain
- Cystitis
- Osteonecrosis of the jaw (rare)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: